Nasal nebulization inhalation of budesonide for chronic rhinosinusitis with nasal polyps: A protocol for systematic review and meta-analysis

• Published in: Medicine (Baltimore) Vol. 99; no. 22; p. e20354
• Main Authors: Zheng, Peng-Ju, Zhang, Yi-Ying, Zhang, Shu-Hua, Liu, Gui-Fang, Wang, Jin-Sheng
• Format: Journal Article
• Language: English
• Published: United States 29.05.2020
• Subjects: Administration, Intranasal; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - therapeutic use; Budesonide - administration & dosage; Budesonide - therapeutic use; Chronic Disease; Humans; Nasal Polyps - drug therapy; Nebulizers and Vaporizers; Rhinitis - drug therapy; Sinusitis - drug therapy
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000020354

Chronic rhinosinusitis and nasal polyps (CRNP) is a common public health concern for general population, and is thought to negatively impact their quality of life. Although previous studies have reported that nasal nebulization inhalation of budesonide (NNIB) can benefit patients with such condition, its conclusions are still inconsistent. Thus, this study will assess the efficacy and safety of NNIB for the treatment of CRNP. To identify any associated studies, we will comprehensively and systematically search Cochrane Library, PubMed, EMBASE, Web of Science, PsycINFO, Cumulative Index to Nursing and Allied Health Literature, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, and China National Knowledge Infrastructure. We will search all electronic databases from inception to the present with no limitations of language and publication status. Two independent reviewers will undertake selection of study, data collection, and study quality evaluation, respectively. Another reviewer will help to settle down any different opinions between both of them. Study quality will be checked using Cochrane risk of bias tool, and statistical analysis will be performed using RevMan 5.3 software. This study will assess the efficacy and safety of NNIB for the treatment of CRNP through assessing primary outcomes of nasal symptoms and polyp sizes, and secondary outcomes of serum cortisol levels, health-related quality of life, and any expected and unexpected adverse events. The results of this study will summarize the up-to-date evidence on assessing the efficacy and safety of NNIB for the treatment of CRNP. INPLASY202040108.